Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 6/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291194 | 1.00 | PRMT5 (0.44) | PRMT5WDR77ATMKMT2AMEN1 | |
| SCHEMBL18291397 | 1.00 | PRMT5 (0.44) | PRMT5WDR77ATMKMT2AMEN1 | |
| SCHEMBL20038466 | 0.84 | MEN1 (0.43) | ATMKMT2AMEN1CACNA1GKCNH2 | |
| SCHEMBL20203394 | 0.84 | PRMT5 (0.47) | PRMT5WDR77ATMKMT2AMEN1 | |
| SCHEMBL20038144 | 0.84 | MEN1 (0.43) | ATMKMT2AMEN1CACNA1GKCNH2 | |
| SCHEMBL20037541 | 0.84 | PIK3CA (0.48) | ATMKMT2AMEN1CACNA1GKCNH2 | |
| SCHEMBL20038104 | 0.84 | MEN1 (0.43) | ATMKMT2AMEN1CACNA1GKCNH2 | |
| SCHEMBL20203391 | 0.84 | PRMT5 (0.47) | PRMT5WDR77ATMKMT2AMEN1 | |
| SCHEMBL20037940 | 0.84 | MEN1 (0.45) | PRMT5WDR77ATMKMT2AMEN1 | |
| SCHEMBL23733410 | 0.83 | PRMT5 (0.46) | PRMT5WDR77ATMKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | PRMT5 1897/4885WDR77 919/4885ATM 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.